Figure 2.

Distribution of individual clinical features among top-performing composite markers. (A) The top 100 composite markers for identifying high-risk IPMNs were decomposed into their individual clinical features. (B) Distributions of cyst diameter among IPMNs and the corresponding sensitivity and specificity for either of these 2 features in the context of the top-performing composite marker listed. The sensitivities and specificities were calculated in the context of the corresponding composite marker (Table 4).